Arcus Biosciences COO sells 50,291 shares after option exercise

Arcus Biosciences (RCUS) reported an insider transaction by its Chief Operating Officer.

Accepted by SEC EDGAR 11/12/2025 - 04:04 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Arcus Biosciences (RCUS) reported an insider transaction by its Chief Operating Officer. On 11/07/2025, the officer exercised 50,291 stock options at $1.2276 per share and sold 50,291 common shares at a $18.9709 weighted average price under a Rule 10b5-1 trading plan. After these trades, the officer directly held 214,232 common shares. The filing notes the sales occurred across multiple trades between $18.59 and $19.42. Remaining derivative holdings include 80,583 stock options with an expiration date of 03/14/2027.

Insider Trade Summary

Exercise and Sale: 50,291 shares ($892K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Jarrett Jennifer

Role Chief Operating Officer

Sold 50,291 shs ($954K)

Approx. gross sale proceeds $954K

Approx. exercise cost $62K

Approx. pre-tax spread $892K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	50,291	$1.2276	$62K
Exercise	Common Stock	50,291	$1.2276	$62K
Sale	Common Stock	50,291	$18.9709	$954K

Holdings After Transaction: Stock Option (Right to Buy) — 80,583 contracts (Direct); Common Stock — 214,232 shares (Direct)

Footnotes (3)

1. F1. The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
2. F2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.59 to $19.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
3. F3. The option is fully vested and currently exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did RCUS report on this Form 4?

The COO exercised 50,291 options at $1.2276 and sold 50,291 shares at a $18.9709 weighted average price on 11/07/2025.

How many Arcus Biosciences shares did the insider hold after the transaction?

Following the reported transactions, the officer directly held 214,232 common shares.

Was the sale under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan.

What was the sale price range for the RCUS shares?

The sale price range was $18.59 to $19.42, with a weighted average of $18.9709.

How many stock options remain and when do they expire?

The officer held 80,583 stock options after the transaction, expiring on 03/14/2027.

What is the insider’s ownership form for the reported holdings?

The reported common share ownership was listed as Direct (D).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jarrett Jennifer

(Last) (First) (Middle)

C/O ARCUS BIOSCIENCES, INC.

3928 POINT EDEN WAY

(Street)

HAYWARD CA 94545

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arcus Biosciences, Inc. [ RCUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/07/2025		M		50,291(1)	A	$1.2276	264,523	D
Common Stock	11/07/2025		S		50,291(1)	D	$18.9709(2)	214,232	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.2276	11/07/2025		M(1)			50,291	(3)	03/14/2027	Common Stock	50,291	$1.2276	80,583	D

Explanation of Responses:

1. The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.59 to $19.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. The option is fully vested and currently exercisable.

Remarks:

	/s/ Carolyn Tang, Attorney-in-Fact	11/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.